Renalase, hypertension, and kidney - The discussion continues

Angiology

Volumn 64, Issue 3, 2013, Pages 181-187

  Malyszko, Jolanta ^a   Malyszko, Jacek S ^a   Rysz, Jacek ^b   Mysliwiec, Michal ^a   Tesar, Vladimir ^c   Levin Iaina, Nomy ^d   Banach, Maciej ^b  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c CHARLES UNIVERSITY   (Czech Republic)

^d SHEBA MEDICAL CENTER   (Israel)

Author keywords

blood pressure; endothelium; genetics; hypertension; kidney diseases; renalase; VAP 1.

Indexed keywords

CREATININE; ENALAPRIL; NORADRENALIN; RECOMBINANT ENZYME; RENALASE PROTEIN; UNCLASSIFIED DRUG;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; ESSENTIAL HYPERTENSION; HENLE LOOP; HUMAN; HYPERTENSION; KIDNEY; KIDNEY TUBULE CELL; NONHUMAN; NORADRENALIN BLOOD LEVEL;

CARDIOVASCULAR DISEASES; DOPAMINE; HUMANS; HYPERTENSION; HYPOPHOSPHATEMIA, FAMILIAL; KIDNEY; MONOAMINE OXIDASE; NATRIURESIS; RECEPTORS, DOPAMINE; RENAL INSUFFICIENCY, CHRONIC;

EID: 84875989982     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319712459212     Document Type: Article

References (72)

1. Santos SF, Peixoto AJ. Hypertension in dialysis. Curr Opin Nephrol Hypertens. 2005 ; 14 (2). 111-118
2. Zoccali C, Mallamaci F, Parlongo S, et al. Plasma norepinephrine predicts survival and incident cardiovascular events in patients with end-stage renal disease. Circulation. 2002 ; 105 (11). 1354-1359
3. Schlaich MP, Socratous F, Hennebry S, et al. Sympathetic activation in chronic renal failure. J Am Soc Nephrol. 2009 ; 20 (5). 933-939
4. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest. 2005 ; 115 (5). 1275-1280
5. Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M. Hypertension and kidney disease: is renalase a new player or an innocent bystander?. J Hypertens. 2012 ; 30 (3). 457-462
6. Medvedev AE, Veselovsky AV, Fedchenko VI. Renalase, a new secretory enzyme responsible for selective degradation of catecholamines: achievements and unsolved problems. Biochemistry (Mosc). 2010 ; 75 (8). 951-958
7. Perticone F, Sciacqua A, Maio R, et al. Asymmetric dimethylarginine, L-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol. 2005 ; 46 (3). 518-523
8. Mancuso P, Antoniotti P, Quarna J, et al. Validation of a standardized method for enumerating circulating endothelial cells and progenitors: flow cytometry and molecular and ultrastructural analyses. Clin Cancer Res. 2009 ; 15 (1). 267-273
9. Inagami T, Naruse M, Hoover R. Endothelium as an endocrine organ. Annu Rev Physiol. 1995 ; 57: 171-189
10. Wolinsky H. A proposal linking clearance of circulating lipoproteins to tissue metabolic activity as a basis for understanding atherogenesis. Circ Res. 1980 ; 47 (3). 301-311
11. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974 ; 290 (13). 697-701
12. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta. 2010 ; 411 (19-20). 1412-1420
13. Li G, Xu J, Wang P, et al. Catecholamines regulate the activity, secretion, and synthesis of renalase. Circulation. 2008 ; 117 (10). 1277-1282
14. Pandini V, Ciriello F, Tedeschi G, Rossoni G, Zanetti G, Aliverti A. Synthesis of human renalase 1 in Escherichia coli and its purification as a FAD-containing holoprotein. Protein Expr Purif. 2010 ; 72 (2). 244-253
15. Luft FC. Renalase, a catecholamine-metabolizing hormone from the kidney. Cell Metab. 2005 ; 1 (6). 358-360
16. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science. 1992 ; 257 (5075). 1407 1409
17. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet. 2008 ; 371 (9626). 1800 1809
18. Yu PH, Wright S, Fan EH, Lun ZR, Gubisne-Harberle D. Physiological and pathological implications of semicarbazide-sensitive amine oxidase. Biochim Biophys Acta. 2003 ; 1647 (1-2). 193 199
19. Malyszko J, Koc-Zorawska E, Malyszko JS, Mysliwiec M. The Transplant Congress ;
20. Lin MS, Li HY, Wei JN, et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem. 2008 ; 41 (16-17). 1362 1367
21. Wang F, Wang N, Xing T, Cao Y, Xiang H. The cloning and expression of renalase and the preparation of its monoclonal antibody. J Shanghai Jiaotong Univ (Sci). 2009 ; 14 (13). 376-379
22. Zbroch E, Malyszko J, Malyszko JS, Koc-Zorawsak E, Mysliwiec M. Renalase, a novel enzyme involved in blood pressure regulation, is related to kidney function but not to blood pressure in hemodialysis patients. Kidney Blood Press Res. 2012 ; 35 (6). 395-399
23. Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M.. Renalase in peritoneal dialysis patients is not related to blood pressure, but to dialysis vintage. Perit Dial Int. 2012 ; 32 (3). 348-351
24. Malyszko J, Zbroch E, Malyszko JS, Koc-Zorawska E, Mysliwiec M. Renalase, a novel regulator of blood pressure, is predicted by kidney function in renal transplant recipients. Transplant Proc. 2011 ; 43 (8). 3004-3007
25. Przybylowski P, Malyszko J, Kozlowska S, Malyszko J, Koc-Zorawska E, Mysliwiec M. Serum renalase, depends on kidney function but not on blood pressure in heart transplant recipients. Transplant Proc. 2011 ; 43 (10). 3888-3891
26. Carey RM. Theodore Cooper lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001 ; 38 (3). 297-302
27. Zeng C, Jose PA. Dopamine receptors: important antihypertensive counterbalance against hypertensive factors. Hypertension. 2011 ; 57 (1). 11-17
28. Felder RA, Jose PA. Mechanisms of disease: the role of GRK4 in the etiology of essential hypertension and salt sensitivity. Nat Clin Pract Nephrol. 2006 ; 2 (11). 637-650
29. Weinman EJ, Biswas R, Steplock D, et al. Increased renal dopamine and acute renal adaptation to a high-phosphate diet. Am J Physiol Renal Physiol. 2011 ; 300 (5). F1123 - F1129
30. Quinones H, Collazo R, Moe OW. The dopamine precursor L-dihydroxyphenylalanine is transported by the amino acid transporters rBAT and LAT2 in renal cortex. Am J Physiol Renal Physiol. 2004 ; 287 (1). F74 - F80
31. Pinho MJ, Serrao MP, Soares-da-Silva P. High-salt intake and the renal expression of amino acid transporters in spontaneously hypertensive rats. Am J Physiol Renal Physiol. 2007 ; 292 (5). F1452 - F1463
32. Krishna GG, Danovitch GM, Beck FW, Sowers JR. Dopaminergic mediation of the natriuretic response to volume expansion. J Lab Clin Med. 1985 ; 105 (2). 214-218
33. Satoh T, Cohen HT, Katz AI. Intracellular signaling in the regulation of renal Na-K-ATPase. I. Role of cyclic AMP and phospholipase A2. J Clin Invest. 1992 ; 89 (5). 1496-1500
34. Zeng C, Sanada H, Watanabe H, Eisner GM, Felder RA, Jose PA. Functional genomics of the dopaminergic system in hypertension. Physiol Genomics. 2004 ; 19 (3). 233-246
35. Shikuma R, Yoshimura M, Kambara S, et al. Dopaminergic modulation of salt sensitivity in patients with essential hypertension. Life Sci. 1986 ; 38 (10). 915-921
36. Morón JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci. 2002 ; 22 (2). 389-395
37. Sampaio-Maia B, Serrão P, Guimarães JT, Vieira-Coelho MA, Pestana M. Renal dopaminergic system activity in the rat remnant kidney. Nephron Exp Nephrol. 2005 ; 99 (2). e46 - e55
38. Sampaio-Maia B, Moreira-Rodrigues M, Pestana M. Role of chronic inhibition of dopamine-metabolizing enzymes in the regulation of renal sodium and phosphate excretion in the rat remnant kidney. Nephron Physiol. 2006 ; 103 (1). 14-24
39. Vermeer C, Ketteler M, Shlipak MG, Whooley MA, Ix JH.. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: The Heart and Soul Study. Ann Intern Med. 2010 ; 152 (10). 640-648
40. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis. 2009 ; 207 (2). 546-551
41. Hsu HJ, Wu MS. Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009 ; 337 (2). 116-122
42. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009 ; 119 (19). 2545-2552
43. Mirza MA, Alsio J, Hammarstedt A, et al. Circulating fibroblast growth factor-23 is associated with fat mass and dyslipidemia in two independent cohorts of elderly individuals. Arterioscler Thromb Vasc Biol. 2011 ; 31 (1). 219-227
44. Marsell R, Mirza MA, Mallmin H, et al. Relation between fibroblast growth factor-23, body weight and bone mineral density in elderly men. Osteoporos Int. 2009 ; 20 (7). 1167-1173
45. Gutiérrez OM, Wolf M, Taylor EN. Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011 ; 6 (12). 2871-2878
46. Yao B, Harris RC., Zhang MZ. Intrarenal dopamine attenuates deoxycorticosterone acetate/high salt-induced blood pressure elevation in part through activation of a medullary cyclooxygenase 2 pathway. Hypertension. 2009 ; 54 (5). 1077-1083
47. Zhang MZ, Yao B, Wang S, et al. Intrarenal dopamine deficiency leads to hypertension and decreased longevity in mice. J Clin Invest. 2011 ; 121 (7). 2845-2854
48. Wu Y, Xu J, Velazquez H, et al. Renalase deficiency aggravates ischemic myocardial damage. Kidney Int. 2011 ; 79 (8). 853-860
49. Baraka A, El Ghotny S. Cardioprotective effect of renalase in 5/6 nephrectomized rats [published online May 24, 2012]. J Cardiovasc Pharmacol Ther. 2012 ;:
50. Desir GV, Tang LQ, Wang P, et al. Renalase lowers ambulatory blood pressure by metabolizing circulating adrenaline. J Am Heart Assoc. 2012 ; 1: e002634
51. Desir G. Novel insights into the physiology of renalase and its role in hypertension and heart disease. Pediatr Nephrol. 2012 ; 27 (5). 719-725
52. Desir GV. Role of renalase in the regulation of blood pressure and the renal dopamine system. Curr Opin Nephrol Hypertens. 2011 ; 20 (1). 31-36
53. Zhao Q, Fan Z, He J, et al. Renalase gene is a novel susceptibility gene for essential hypertension: a two-stage association study in northern Han Chinese population. J Mol Med. 2007 ; 85 (8). 877-885
54. Farzaneh-Far R, Desir GV, Na B, Schiller NB, Whooley MA. A functional polymorphism in renalase (Glu37Asp) is associated with cardiac hypertrophy, dysfunction, and ischemia: data from the heart and soul study. PLoS One. 2010 ; 5 (10). e13496
55. Góra J, Placha G, Symonides B, et al. A functional polymorphism in renalase gene (glu37asp) is associated with heart rate, cardiac hypertrophy and urinary noradrenaline in patients with pheochromocytoma. J Hypertens. 2012 ; 30 (suppl A). e527 - e528
56. Stec A, Semczuk A, Furmaga J, Ksiazek A, Buraczynska M. Polymorphism of the renalase gene in end-stage renal disease patients affected by hypertension [published online May 26, 2011]. Nephrol Dial Transplant. 2011 ;:
57. Buraczynska M, Zukowski P, Buraczynska K, Mozul S, Ksiazek A. Renalase gene polymorphisms in patients with type 2 diabetes, hypertension and stroke. Neuromolecular Med. 2011 ; 13 (4). 321-327
58. Schlaich M, Socratous F, Eikelis N, Chopra R, Lambert G, Hennebry S. Renalase plasma levels are associated with systolic blood pressure in patients with resistant hypertension. J Hypertens. 2010 ; 28 (p). e437
59. Yano Y, Hoshide S, Etoh T, Tamaki N, Yokota N, Kario K. Synergistic effect of chronic kidney disease and high circulatory norepinephrine level on stroke risk in Japanese hypertensive patients. Atherosclerosis. 2011 ; 219 (1). 273-279
60. Mallamaci F, Tripepi G, Maas R, Malatino L, Böger R, Zoccali C. Analysis of the relationship between norepinephrine and asymmetric dimethyl arginine levels among patients with end-stage renal disease. J Am Soc Nephrol. 2004 ; 15 (2). 435-441
61. Malyszko J, Koc-Zorawska E, Malyszko JS, Kozminski P, Zbroch E, Mysliwiec M. Renalase, stroke and hypertension in hemodialyzed patients. Ren Fail. 2012 ; 34 (6). 727-731
62. Zbroch E, Malyszko J, Malyszko J, Koc-Zorawska E, Mysliwiec M. Paris: ERA-EDTA Congress ;
63. Shaw G, Morse S, Ararat M, Graham FL. Preferential transformation of human neuronal cells by human adenoviruses and the origin of HEK 293 cells. FASEB J. 2002 ; 16 (8). 869-871
64. Athyros VG, Hatzitolios AI, Karagiannis A, Karagiannis A, Mikhailidis DP. Improving the implementation of current guidelines for the management of major coronary heart disease risk factors by multifactorial intervention. The IMPERATIVE renal analysis. Arch Med Sci. 2011 ; 7 (6). 984-992
65. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A. The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci. 2010 ; 6 (4). 539-544
66. Gluba A, Mikhailidis DP, Lip GY, Hannam S, Rysz J, Banach M. Metabolic syndrome and renal disease [published online February 2, 2012]. Int J Cardiol. 2012 ;:
67. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The rise and fall of hypertension: lessons learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011 ; 5 (2). 174-179
68. Vulic D, Loncar S, Krneta M, et al. Risk factor control and adherence to treatment in patients with coronary heart disease in the Republic of Srpska, Bosnia and Herzegovina in 2005-2006. Arch Med Sci. 2010 ; 6 (2). 270-275
69. Barylski M, Malyszko J, Rysz J, MyÅliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011?. Arch Med Sci. 2011 ; 7 (6). 1055-1066
70. Gluba A, Banach M, Hannam S, Mikhailidis DP, Sakowicz A, Rysz J. The role of toll-like receptors in renal diseases. Nat Rev Nephrol. 2010 ; 6 (4). 224-235
71. Cicero AF, Ertek S. Preclinical and clinical evidence of nephro- and cardiovascular protective effects of glycosaminoglycans. Arch Med Sci. 2010 ; 6 (4). 469-477
72. Zbroch E, Malyszko J, Malyszko J, Koc-Åórawska E, MyÅliwiec M. Renalase, kidney function, and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn. 2012 ; 122 (1-2). 40-44